Indian Pacing Electrophysiol J. 2025 Aug 2:S0972-6292(25)00109-3. doi: 10.1016/j.ipej.2025.07.018. Online ahead of print.
ABSTRACT
At the beginning of the last century, quinidine had been shown to be highly effective in the management of atrial fibrillation and soon after of ventricular arrhythmias. At the end of the same century, quinidine was quickly abandoned, and its manufacturing ceased, resulting in limited accessibility across numerous countries. Paradoxically, this decline in use occurred alongside accumulating evidence supporting quinidine's therapeutic benefit in managing rare, life-threatening ventricular arrhythmias occurring in patients with no organic heart disease (Idiopathic ventricular fibrillation, Brugada syndrome, Early repolarization syndrome, Short QT syndrome, Multifocal ectopic Purkinje-related premature contractions), as well as those with organic heart disease involving the Purkinje network such as those occurring after acute myocardial infarction or in patients with hypertrophic cardiomyopathy. The present review will extensively deal with all these topics.
PMID:40759243 | DOI:10.1016/j.ipej.2025.07.018